DK3528838T5 - Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis - Google Patents

Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis Download PDF

Info

Publication number
DK3528838T5
DK3528838T5 DK17780280.8T DK17780280T DK3528838T5 DK 3528838 T5 DK3528838 T5 DK 3528838T5 DK 17780280 T DK17780280 T DK 17780280T DK 3528838 T5 DK3528838 T5 DK 3528838T5
Authority
DK
Denmark
Prior art keywords
antibodies
treatment
atopic dermatitis
atopic
dermatitis
Prior art date
Application number
DK17780280.8T
Other languages
Danish (da)
English (en)
Other versions
DK3528838T3 (da
Inventor
Chinyu Lin
Theodore A Omachi
Ryan P Owen
Karl Yen
Yanan Zheng
Kendra Debusk
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3528838T3 publication Critical patent/DK3528838T3/da
Publication of DK3528838T5 publication Critical patent/DK3528838T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17780280.8T 2016-09-23 2017-09-22 Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis DK3528838T5 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662398713P 2016-09-23 2016-09-23
US201762527204P 2017-06-30 2017-06-30
US201762530683P 2017-07-10 2017-07-10
US201762539037P 2017-07-31 2017-07-31
PCT/US2017/052891 WO2018057849A1 (en) 2016-09-23 2017-09-22 Uses of il-13 antagonists for treating atopic dermatitis

Publications (2)

Publication Number Publication Date
DK3528838T3 DK3528838T3 (da) 2023-08-28
DK3528838T5 true DK3528838T5 (da) 2024-09-02

Family

ID=60020628

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17780280.8T DK3528838T5 (da) 2016-09-23 2017-09-22 Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis

Country Status (28)

Country Link
US (3) US11434286B2 (cg-RX-API-DMAC7.html)
EP (2) EP4268845A3 (cg-RX-API-DMAC7.html)
JP (1) JP6995844B2 (cg-RX-API-DMAC7.html)
KR (1) KR102557643B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715201A (cg-RX-API-DMAC7.html)
AU (1) AU2017330405B2 (cg-RX-API-DMAC7.html)
CA (1) CA3031589C (cg-RX-API-DMAC7.html)
CY (2) CY1126255T1 (cg-RX-API-DMAC7.html)
DK (1) DK3528838T5 (cg-RX-API-DMAC7.html)
ES (1) ES2958593T3 (cg-RX-API-DMAC7.html)
FI (2) FI3528838T3 (cg-RX-API-DMAC7.html)
FR (1) FR24C1017I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20231015T1 (cg-RX-API-DMAC7.html)
HU (2) HUE063135T2 (cg-RX-API-DMAC7.html)
IL (1) IL265473B2 (cg-RX-API-DMAC7.html)
LT (2) LT3528838T (cg-RX-API-DMAC7.html)
MX (1) MX2019002672A (cg-RX-API-DMAC7.html)
NL (1) NL301269I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ790629A (cg-RX-API-DMAC7.html)
PL (1) PL3528838T3 (cg-RX-API-DMAC7.html)
PT (1) PT3528838T (cg-RX-API-DMAC7.html)
RS (1) RS64550B1 (cg-RX-API-DMAC7.html)
RU (1) RU2752785C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201900845YA (cg-RX-API-DMAC7.html)
SI (1) SI3528838T1 (cg-RX-API-DMAC7.html)
TW (1) TWI787203B (cg-RX-API-DMAC7.html)
UA (1) UA124269C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018057849A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067896T2 (hu) 2016-04-27 2024-11-28 Abbvie Mfg Management Unlimited Company Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros
NZ790629A (en) * 2016-09-23 2025-11-28 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
US12187788B2 (en) * 2020-03-23 2025-01-07 Medimmune Limited Methods for treating atopic dermatitis and related disorders
EP4126943A1 (en) * 2020-03-23 2023-02-08 MedImmune Limited Methods for treating atopic dermatitis and related disorders
MX2023004113A (es) * 2020-10-09 2023-06-29 Kyowa Kirin Co Ltd Metodo para el tratamiento de enfermedades relacionadas con ox40.
JP2024511078A (ja) * 2021-03-17 2024-03-12 レセプトス エルエルシー 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法
TWI847170B (zh) * 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) * 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
AU2022345969A1 (en) * 2021-09-15 2024-03-07 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
CN119630699A (zh) * 2022-05-05 2025-03-14 德米拉公司 用于治疗特应性皮炎的il-13抗体
CR20250009A (es) 2022-06-17 2025-05-07 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13 y métodos de uso
JP2025530181A (ja) * 2022-09-06 2025-09-11 アスラン ファーマシューティカルズ ピーティーイー リミテッド 皮膚炎患者における不眠または睡眠障害の治療
KR102773781B1 (ko) 2023-03-14 2025-02-28 주식회사 지오비스타 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도
AU2024235509A1 (en) 2023-03-14 2025-09-18 Geovista Inc. Antibody specifically binding to interleukin-13, and use thereof
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
KR20250017610A (ko) 2023-07-27 2025-02-04 김천균 아토피의 치료와 예방용 조성물 및 그 제조방법
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025155874A1 (en) * 2024-01-18 2025-07-24 Enveda Therapeutics, Inc. Methods and compounds for modulating immune response

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
LT2805728T (lt) * 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2557778T3 (es) 2004-11-24 2016-01-28 Group Ab Shl Dispositivo de inyección
DE602005008404D1 (de) 2005-06-01 2008-09-04 Shl Medical Ab Medikamentenabgabevorrichtung
DK1885414T3 (da) 2005-06-01 2013-02-11 Shl Group Ab Indretning til afgivelse af et lægemiddel
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
KR101461263B1 (ko) * 2005-10-21 2014-11-17 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008204901A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2652498B1 (en) * 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
AU2013204900B2 (en) * 2010-12-16 2016-11-10 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US9022982B2 (en) 2011-06-17 2015-05-05 Shl Group Ab Injection device
USRE50423E1 (en) 2011-06-17 2025-05-13 Shl Medical Ag Injection device
SI3091029T1 (sl) * 2011-10-31 2023-03-31 F. Hoffmann - La Roche Ag Pripravki protiteles proti IL13
BR112015005048A8 (pt) 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
HK1220919A1 (zh) 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
KR20160113700A (ko) * 2014-01-27 2016-09-30 메디뮨 엘엘씨 천식 폐에서의 il-13 활성화의 말초 바이오마커로서의 디펩티딜 펩티다제-4(dpp4/cd26)
HK1247287A1 (zh) 2015-03-16 2018-09-21 F. Hoffmann-La Roche Ag 检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
NZ790629A (en) * 2016-09-23 2025-11-28 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis

Also Published As

Publication number Publication date
TWI787203B (zh) 2022-12-21
EP3528838B1 (en) 2023-07-19
MX2019002672A (es) 2019-07-04
CN109715201A (zh) 2019-05-03
FI3528838T3 (fi) 2023-10-02
FIC20240013I1 (fi) 2024-04-30
IL265473B2 (en) 2024-01-01
CA3031589C (en) 2025-05-06
PT3528838T (pt) 2023-09-04
CY1126255T1 (el) 2025-05-09
US20220372131A1 (en) 2022-11-24
HUS2400011I1 (hu) 2024-06-28
NL301269I2 (nl) 2024-05-22
NZ790629A (en) 2025-11-28
CY2024013I2 (el) 2025-05-09
EP4268845A2 (en) 2023-11-01
JP6995844B2 (ja) 2022-02-04
EP4268845A3 (en) 2024-02-28
KR102557643B1 (ko) 2023-07-20
DK3528838T3 (da) 2023-08-28
KR20190053184A (ko) 2019-05-17
NZ750179A (en) 2025-03-28
FR24C1017I1 (fr) 2024-06-28
CA3031589A1 (en) 2018-03-29
AU2017330405B2 (en) 2024-02-01
US20240228606A1 (en) 2024-07-11
RU2019103943A (ru) 2020-10-23
TW201815415A (zh) 2018-05-01
CY2024013I1 (el) 2025-05-09
EP3528838A1 (en) 2019-08-28
WO2018057849A1 (en) 2018-03-29
US11434286B2 (en) 2022-09-06
RS64550B1 (sr) 2023-09-29
JP2019533646A (ja) 2019-11-21
UA124269C2 (uk) 2021-08-18
PL3528838T3 (pl) 2023-12-18
LTPA2024512I1 (cg-RX-API-DMAC7.html) 2024-05-27
HUE063135T2 (hu) 2023-12-28
IL265473B1 (en) 2023-09-01
AU2017330405A1 (en) 2019-02-21
IL265473A (en) 2019-05-30
SI3528838T1 (sl) 2023-10-30
LTC3528838I2 (cg-RX-API-DMAC7.html) 2025-10-10
FR24C1017I2 (fr) 2024-10-25
RU2752785C2 (ru) 2021-08-04
LT3528838T (lt) 2023-10-10
US20190270803A1 (en) 2019-09-05
SG11201900845YA (en) 2019-02-27
HRP20231015T1 (hr) 2023-12-08
RU2019103943A3 (cg-RX-API-DMAC7.html) 2020-12-29
ES2958593T3 (es) 2024-02-12

Similar Documents

Publication Publication Date Title
DK3528838T3 (da) Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis
EP3426686C0 (en) Humanized Anti-PACAP Antibodies and Their Uses
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
IL258245A (en) Anti-variant fc-region antibodies and methods of use
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
DK3248986T3 (da) Variable immunoglobulindomæner
LT3148579T (lt) Anti-gitr antikūnai ir jų panaudojimo būdai
LT3303394T (lt) Anti-ctla-4 antikūnai ir jų naudojimo būdai
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
LT3250610T (lt) Fcrn antikūnai ir jų panaudojimo būdai
EP3285633A4 (en) STEERING MICROENDOSCOPE
FR3018941B1 (fr) Pilotage de vehicules en convoi
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
IL247002A0 (en) Anti-il-17/il-13 bispecific antibodies and their uses
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
LT3491025T (lt) Fcrn antikūnai ir jų panaudojimo būdai
DK3524255T3 (da) Sammensætning til behandling af acne
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3478719T6 (da) Anvendelse af anti-sclerostin-antistoffer i behandlingen af osteogenesis imperfecta